Skip to main content
TipRanks
Go Ultimate75% OFF

AEON Biopharma (AEON) Stock Price & Analysis

241 Followers

AEON Stock Chart & Stats

$0.15-$0.01(-3.16%)
At close: 4:00 PM EST
$0.15$0.2$0.25$0.3Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.15 - $0.17
52-Week Range
$0.13 - $1.45
Previous Close
$0.16
Volume
N/A
Average Volume (3M)
1.06M
Market Cap
$9.04M
Enterprise Value
$35.69M
Total Cash (Recent Filing)
$3.43M
Total Debt (Recent Filing)
$2.77M
Price to Earnings (P/E)
―
Beta
1.55
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

ABP-450 Regulatory Pathway

The FDA’s agreement in principle provides a defined development route for ABP-450 and may reduce the need for a standalone comparative efficacy study. If execution is successful, the streamlined evidence package could improve development efficiency and advance the candidate toward a 2027 BLA filing.

Extended Financial Runway

Additional financing and restored exchange compliance give AEON more time to execute its ABP-450 development plan without an immediate funding interruption. The extended runway supports planned regulatory and clinical activities, although future progress remains dependent on continued access to capital.

Improving Cash-Burn Trend

Although AEON continues to consume cash, the narrowing outflow indicates some improvement in financial efficiency compared with prior periods. If maintained, lower burn could extend the company’s available funding horizon and allow more of its capital to support the ABP-450 program.

Bears Say

Pre-Revenue Operating Model

AEON has not yet established recurring commercial revenue and continues to absorb substantial development costs. This leaves the company without operating leverage from product sales, makes progress dependent on regulatory success, and increases the importance of future financing or partnership support.

Negative Equity And Small Asset Base

Persistent negative equity and a small asset base indicate constrained balance-sheet strength and limited financial flexibility. This weakens the company’s ability to absorb setbacks, fund development internally, or negotiate from a position of strength, while volatile debt levels add to capital-structure uncertainty.

Ongoing External Funding Dependence

Sustained negative operating and free cash flow means AEON cannot currently finance its activities through internally generated cash. Continued development therefore depends on additional capital or strategic transactions, creating funding risk and potential dilution before commercial products generate revenue.

AEON Biopharma News

AEON FAQ

What was AEON Biopharma’s price range in the past 12 months?
AEON Biopharma lowest stock price was $0.13 and its highest was $1.45 in the past 12 months.
What is AEON Biopharma’s market cap?
AEON Biopharma’s market cap is $9.04M.
When is AEON Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AEON Biopharma’s earnings last quarter?
AEON Biopharma released its earnings results on Nov 18, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.09.
Is AEON Biopharma overvalued?
According to Wall Street analysts AEON Biopharma’s price is currently Undervalued.
Does AEON Biopharma pay dividends?
AEON Biopharma does not currently pay dividends.
What is AEON Biopharma’s EPS estimate?
AEON Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AEON Biopharma have?
AEON Biopharma has 59,084,675 shares outstanding.
What happened to AEON Biopharma’s price movement after its last earnings report?
AEON Biopharma reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -1.818%.
Which hedge fund is a major shareholder of AEON Biopharma?
Hedge funds hold AEON Biopharma shares: the largest hedge-fund position in AEON Biopharma is 71,888,625 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology